Fitxers

878443.pdf (3.53 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-02-01

Llicència de publicació

cc-by (c) Bonilla-Vidal, L. et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227407

Nanostructured lipid carriers co-encapsulating Apigenin and Melatonin: An innovative strategy against cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.matdes.2024.113573

Resum

Cancer remains a global health concern, being one of the leading causes of premature death worldwide. In 2020, around 19 million people were diagnosed with cancer, leading to approximately 10 million deaths [1], [2]. Conventional cancer therapies, including chemotherapy and radiotherapy, often exhibit adverse effects and suboptimal treatment outcomes. Specifically, chemotherapy is frequently administered to over 50 % of cancer patients, but it can simultaneously impact both healthy and cancerous cells, causing significant side effects. Moreover, these therapies can induce chemoresistance, compromising their effectiveness over time [3], [4]. As a result, there is an urgent need for the development of innovative therapeutic strategies to address these limitations.

Matèries

Càncer, Melatonina, Nanotecnologia, Epigenètica

Matèries (anglès)

Cancer, Melatonin, Nanotechnology, Epigenetics

Citació

Col·leccions

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Citació

BONILLA VIDAL, Lorena, et al. Nanostructured lipid carriers co-encapsulating Apigenin and Melatonin: An innovative strategy against cancer. Materials & Design. 2025. Vol. 250. ISSN 0264-1275. [consulta: 10 de maig de 2026]. Disponible a: https://hdl.handle.net/2445/227407

Exportar metadades

JSON - METS

Compartir registre